CTNM: Contineum Therapeutics, Inc. Company Short-Term Debt

Symbol and logo of brand contineum-tx.com (CTNM)

Contineum Therapeutics, Inc. (CTNM) generates revenue through the development of advanced therapies for nervous system pathologies, including the treatment of demyelination. The team of developers and chemists remains stable due to attractive stock options, and the staff is currently being expanded with clinical monitoring specialists. This price chart illustrates the dynamics of a specific short-term debt, which currently stands at 0.00.

CTNM (Contineum Therapeutics Inc) Company Short-Term Debts history from 04/06/2024 to 11/01/2026

Financial and market metric breakdowns for Contineum Corp (CTNM)

- current quotes and average value forecast:
Price Chart Contineum Therapeutics|CTNM - Fair Value Consensus
- market capitalization information:
Market Value Contineum Therapeutics, Inc.|CTNM - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Contineum Therapeutics|CTNM - Book Capitalization|Market Cap to Net Assets Ratio contineum-tx.com|CTNM - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Contineum Therapeutics, Inc.|CTNM - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Contineum Therapeutics, Inc.|CTNM - Company Cumulative Debt|Debt to Book Value Contineum Therapeutics, Inc.|CTNM - Company Long-Term Debts|Company Short-Term Debt Contineum Therapeutics|Quick Liquidity contineum-tx.com
- net income and valuation multiples indicators:
CTNM - Company Net Income
Basic company analysis:Contineum Therapeutics - CTNM
Mass-produced product of Contineum Corp

Long-term investing requires strict liquidity control to minimize capital losses. For Contineum Therapeutics, Inc. (CTNM), which lacks commercial products, this risk is amplified by a dependence on external funding. Total short-term debt measures obligations on loans and notes with maturities of up to one year. The trend of this metric reflects management discipline in debt administration. A steady reduction in this burden confirms the financial stability of this high-risk biotech asset.

Competitors of Contineum Therapeutics, Inc. (CTNM)

JAZZ - Company Short-Term Debt|Company Short-Term Loans and Borrowings CYTK (Cytokinetics Inc.)|PTC Therapeutics Corp (PTCT) - Company Short-Term Debt|Company Current Liabilities Scholar Rock Inc.|CNTA (Centessa Pharmaceuticals) - Company Short-Term Debts|Company Short-Term Debts dyne-tx.com|Company Current Liabilities EWTX (Edgewise Therapeutics, Inc.)|RAPP (Rapport Therapeutics Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Alumis Corp ALMS|ZVRA: Company Short-Term Indebtedness|Larimar Therapeutics - Company Short-Term Debts|Short-Term Debt Capricor Therapeutics|TRDA (Entrada Therapeutics, Inc.) - Company Current Liabilities|Channel Therapeutics Inc. (PTHS) - Company Short-Term Debts|Company Short-Term Debt MediciNova Inc.|SER: Company Short-Term Loans and Borrowings|Company Short-Term Debt BioXcel Therapeutics (BTAI)|PMN - Short-Term Debt|Company Short-Term Debt Apimeds Pharmaceuticals US APUS|AEON Biopharma Inc. - Company Short-Term Debt|NLSP - Company Short-Term Debt|Short-Term Debt Bionomics Limited|HUGE: Company Short-Term Debts|Short-Term Indebtedness reatapharma.com RETA